USCOM LIMITED — Regulatory Filings 2012

Jun 25, 2012

Uscom Limited ABN 35 091 028 090 Suite 1, Level 7, 10 Loftus Street Sydney NSW 2000 Australia T +612 9247 4144 F +612 9247 8157 www.uscom.com.au

M A R K E T A N N O U N C E M E N T

New Research: USCOM the best Doppler cardiac monitoring method

Tuesday 26th of June 2012:

Uscom today announced the publication of new clinical evidence which was presented at the World Congress of Anesthesia 2012 and published in the British Journal of Anesthesia, further confirming the gold standard status of the USCOM cardiac output monitor in Aneasthesia.

Uscom Chief Executive Rob Phillips said, “This new study in the BJA confirms that USCOM can replace the CardioQ device in anaesthesia. The CardioQ device has outcomes evidence confirming lifesaving and cost limiting benefits which is being used to support Government adoption guidelines in the UK NHS. The study demonstrates that USCOM can achieve superior results noninvasively and at reduced cost. This study also confirms USCOM’s claim to be the gold standard platform cardiac monitoring technology”.

The publication by Professor Lester Critchley from the Prince of Wales Hospital in Hong Kong, compared USCOM with an alternate method endorsed by the United Kingdom NHS NICE Guidelines, CardioQ Doppler, in high risk surgery patients during anaesthesia. Professor Critchley found that while both methods were acceptable, the CardioQ method was inaccurate at low and high cardiac output values, the values where accuracy becomes critical, while USCOM remained accurate throughout.

The CardioQ Doppler requires insertion of a single patient use intra-oesophageal probe costing between $100 to $200,AUD while USCOM is totally noninvasive, reusable and has no consumables. Anesthesia is an important clinical application and growing market for USCOM.

This study follows the recognition by the UK NHS Intraoperative Fluid Management Technologies Pack published by the United Kingdom NHS Technology Adoption Centre last month citing USCOM as a preferred method of fluid management in high risk surgery.

Reference: Critchley LA. Differences between CardioQ and USCOM Doppler cardiac output readings in high risk surgical patients. British Journal of Anaesthesia 2012; 108(S2): ii113. doi:10.1093/bja/aer479

About Uscom

Uscom Limited is an Australian medical device company which listed on the Australian Stock Exchange in December 2003. Uscom has developed a Non Invasive Cardiac Output Monitor. The USCOM is a simple, cost-effective and non-invasive device that measures heart function, detects irregularities and guides treatment. The USCOM device has major applications in Paediatrics, Emergency and Intensive Care Medicine and Anesthesia, and is a tool of choice for management of adult and paediatric sepsis, and for the guidance of fluid therapy.

USCOM has global regulatory approval and the device is currently marketed in North America, South America, Europe, the Middle East, Australia & New Zealand, China and SE Asia.

Uscom Contacts Rob Phillips Executive Chairman rob@uscom.com.au

Tom Rowe Company Secretary secretary@uscom.com.au